NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$21.66 USD
+0.38 (1.79%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $21.70 +0.04 (0.18%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
NewAmsterdam Pharma Company N.V.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NAMS 21.66 +0.38(1.79%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
NewAmsterdam Pharma's Obicetrapib Shows Promise in Alzheimer's Biomarker Reduction | NAMS stock news
NewAmsterdam Pharma (NAMS) Releases Alzheimer's Biomarker Data from BROADWAY Trial
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically ...
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC